NSE / BSEHealthcare
β‚Ή193.40+1.35+0.70%
P/E31.7Mkt Capβ‚Ή22.36 K CrEV/EBITDA27.6

PIRAMAL PHARMA LIMITED

P/E31.7Mkt Capβ‚Ή22.36 K CrEV/EBITDA27.6
Company Profile

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 5.36% over 1Y
Monthly Returns

Historically, Jul has averaged the highest return (+9.5%); Feb the lowest (-12.7%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-10.3%Negative MonthJan 2026: -10.30%+1.0%Neutral MonthFeb 2026: +1.04%-12.6%Negative MonthMar 2026: -12.62%+18.7%Positive MonthApr 2026: +18.65%+8.4%Positive MonthMay 2026: +8.40%-4.2%Negative MonthJun 2026: -4.16%+15.0%*Positive MonthJul 2026: +14.98%β€”β€”β€”β€”β€”
2025-12.4%Negative MonthJan 2025: -12.38%-18.4%Negative MonthFeb 2025: -18.44%+18.2%Positive MonthMar 2025: +18.19%-6.0%Negative MonthApr 2025: -5.99%-2.3%Negative MonthMay 2025: -2.25%-1.4%Neutral MonthJun 2025: -1.41%-3.1%Negative MonthJul 2025: -3.10%-6.8%Negative MonthAug 2025: -6.85%+4.0%Positive MonthSep 2025: +3.98%+4.6%Positive MonthOct 2025: +4.64%-6.2%Negative MonthNov 2025: -6.21%-8.0%Negative MonthDec 2025: -8.03%
2024+3.9%Positive MonthJan 2024: +3.89%-8.6%Negative MonthFeb 2024: -8.63%-2.2%Negative MonthMar 2024: -2.16%+11.4%Positive MonthApr 2024: +11.44%+3.2%Positive MonthMay 2024: +3.17%+6.0%Positive MonthJun 2024: +6.01%+12.1%Positive MonthJul 2024: +12.13%+7.2%Positive MonthAug 2024: +7.18%+21.3%Positive MonthSep 2024: +21.27%+17.2%Positive MonthOct 2024: +17.23%+0.1%Neutral MonthNov 2024: +0.06%-1.0%Neutral MonthDec 2024: -1.02%
2023-8.6%Negative MonthJan 2023: -8.58%-24.8%Negative MonthFeb 2023: -24.83%-13.2%Negative MonthMar 2023: -13.21%+3.5%Positive MonthApr 2023: +3.54%+14.8%Positive MonthMay 2023: +14.78%+14.0%Positive MonthJun 2023: +14.04%+13.9%Positive MonthJul 2023: +13.90%-3.0%Negative MonthAug 2023: -3.01%-0.4%Neutral MonthSep 2023: -0.44%+2.4%Positive MonthOct 2023: +2.35%+21.2%Positive MonthNov 2023: +21.17%+9.7%Positive MonthDec 2023: +9.72%
2022β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”-19.1%Negative MonthNov 2022: -19.06%-14.6%Negative MonthDec 2022: -14.62%
AvgΒ±SD-6.8%Β±6.3%-12.7%Β±9.8%-2.5%Β±12.7%+6.9%Β±9.2%+6.0%Β±6.3%+3.6%Β±7.1%+9.5%Β±7.3%-0.9%Β±5.9%+8.3%Β±9.4%+8.1%Β±6.5%-1.0%Β±14.5%-3.5%Β±9.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 5 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.122x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή5.29 K Crβ–² 20.4%
EBITDA Growthβ€”
Net Profitβ‚Ή691.00 Crβ–² 76.7%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 137.1%
Revenue CAGR 5Y0.0%
EBITDA CAGR 5Y0.0%
Net Profit CAGR 5Y0.0%
NP Growth 1Y76.7%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή5.29 K Crβ€”β‚Ή691.00 Crβ€”β€”9.3%20.4%76.7%
Mar 2024β‚Ή4.39 K Crβ€”β‚Ή391.00 Crβ€”β€”5.8%27.5%458.6%
Mar 2023β‚Ή3.44 K Crβ€”β‚Ή70.00 Crβ€”β€”1.3%3.1%-81.0%
Mar 2022β‚Ή3.34 K Crβ€”β‚Ή368.00 Crβ€”β€”7.2%13.6%-35.7%
Mar 2021β‚Ή2.94 K Crβ€”β‚Ή572.00 Crβ€”β€”13.9%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales2,9393,3403,4434,3905,2865,035
Total Expenses2,3202,8643,3453,7724,2454,228
EBIT / Operating Profit619476986181,041807
OPM %21%14%3%14%20%16%
Other Income216209334202207447
Finance Costs557116107115103
Depreciation & Amortisation144165192205222237
Profit Before Tax687462124508911914
Tax %17%20%44%23%24%-
Net Profit / PAT57236870391691706
EPS (β‚Ή)--0.532.965.225.32
Dividend Payout %0%18%0%4%3%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
PIRAMAL PHARMA LIMITEDthis co.β‚Ή22.36 K Crβ‚Ή5.29 K Cr31.702.8927.5620.4%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of PIRAMAL PHARMA LIMITED and the metrics that matter.

Browse the full Equiscale Academy